Global Cancer Diagnostics Market Outlook, 2031
The Global Cancer Diagnostics Market is segmented into By Product Type (Consumables and reagents (Antibodies, Kits & Reagents, Probes), Instruments (Pathology-based Instruments, Imaging Instruments, Biopsy Instruments); By Technology (IVD testing, Anatomic pathology, Diagnostic imaging, Biopsy); By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Others); By End User (Hospitals, iagnostic Centres, Research Institutes, Others).
- Bonafide Research
- 27-10-2026
- Pages : 199
- Figures : 36
- Tables : 94
- Region : Global
- Category : Lifescience & Healthcare
- Medical Devices
- Schedule a Call
-
Sikandar Kesari — Research Analyst
The Global Cancer Diagnostics Market is expected to cross 168.96 Billion market size by 2031, with 8.45% CAGR by 2026-31, driven by the rising cancer burden.
- Historical Period2020-2024
- Base Year2025
- Forecast Period2026-2031
- Market Size (2025) USD 105.1 Billion
- Market Size (2031) USD 168.96 Billion
- CAGR (2026-2031) 8.45%
- Largest MarketNorth America
- Fastest Market Asia-Pacific
- Format
Featured Companies
- 1. Abbott Laboratories
- 2. Danaher Corporation
- 3. Siemens Healthineers
- 4. Agilent Technologies, Inc.
- 5. Thermo Fisher Scientific Inc
- 6. Exact Sciences Corp
- 7. Myriad Genetics, Inc
- 8. QIAGEN N.V.
- 9. Illumina, Inc
- More...
Cancer Diagnostics Market Analysis
The global cancer diagnostics market encompasses the complete ecosystem of technologies, tools, and medical procedures utilized to detect, identify, and monitor malignant tumors. Functioning as a critical cornerstone of modern healthcare, its primary relevance lies in providing clinicians with precise actionable insights needed to identify cancer at early, treatable stages and tailor personalized therapeutic strategies through precision oncology. The importance of this sector is magnified by the escalating worldwide burden of cancer, where early detection dramatically improves patient survival rates and optimizes healthcare expenditure. Market growth is aggressively propelled by key drivers such as an expanding global aging population, rising lifestyle-related cancer risks, and technological breakthroughs like Next-Generation Sequencing (NGS), liquid biopsies, AI-driven digital pathology, and advanced imaging modalities like PET and MRI scans. Additionally, prominent global healthcare and scientific associations including the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and global health organizations like the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) play a pivotal role in shaping this landscape. These bodies drive vital activities by funding cutting-edge diagnostic research, establishing standardized clinical guidelines, advocating for widespread screening access, and hosting global congresses to showcase emerging biomarker discoveries. Commercial leaders in this space continuously engage in strategic activities, including high-stakes diagnostic assay R&D, cross-border corporate acquisitions, and partnerships with public health entities to deploy mobile diagnostic units and community screening programs. Ultimately, the synergistic activities between clinical researchers, governing associations, and diagnostic companies ensure the continuous evolution of minimally invasive, highly accurate diagnostic tools to combat cancer globally. According to the research report, “Global Cancer Diagnostics Market Overview, 2031” published by Bonafide Research, the Global Cancer Diagnostics Market is expected to cross 168.96 Billion market size by 2031, with 8.45% CAGR by 2026-31. Leading industry giants such as Roche Diagnostics, Thermo Fisher Scientific, Illumina, Abbott Laboratories, GE HealthCare, and Siemens Healthineers drive this sector through advanced molecular testing, imaging, and tissue-based solutions. Recent breakthroughs highlight rapid commercial evolution; for instance, Roche expanded its automated diagnostic portfolio with BenchMark ULTRA PLUS, Illumina expanded oncology genomic profiling via its NovaSeq X platforms, and Abbott secured FDA approval for its Alinity high-risk HPV screening assay. Furthermore, Quest Diagnostics acquired Haystack Oncology to pioneer early minimal residual disease (MRD) detection. Immense market opportunities stem from expanding AI-driven digital pathology, liquid biopsy assays targeting circulating tumor DNA, and novel biomarker discoveries that enable minimally invasive patient stratification. A rigorous supply chain analysis reveals a multi-tiered ecosystem reliant on precision inputs. Upstream supplier networks provide high-grade biological materials, monoclonal antibodies, specialized enzymes, microfluidic chips, and rare metals for diagnostic imaging instruments. Midstream manufacturers integrate these components to produce complex next-generation sequencing (NGS) platforms, PCR reagents, and automated slide stainers under stringent global regulatory oversight. Downstream distribution operates through specialized cold-chain logistics networks, directly supplying hospitals, academic research institutes, independent diagnostic reference laboratories, and outpatient care centers. However, the supply chain faces ongoing vulnerabilities, including raw material supply bottlenecks, temperature-sensitive shipment disruptions, single-source reagent dependencies, and regional regulatory compliance variations. Emerging markets in the Asia-Pacific region, particularly India and China, represent the fastest-growing supply and demand hubs, accelerating regional manufacturing and distribution investments to democratize diagnostic access.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamics
Market Drivers
• Escalating global cancer burden and aging demographics: The persistent increase in global cancer incidence serves as the primary driver for diagnostic market expansion. According to global health estimates, the combination of an aging global population and lifestyle-induced risk factors (such as smoking, poor diet, and environmental exposures) has led to millions of new cancer diagnoses annually. Because early-stage detection directly correlates with significantly higher 5-year survival rates and reduced systemic healthcare costs, public and private healthcare systems worldwide are prioritizing routine cancer screening programs, driving sustained demand for both diagnostic consumables and advanced imaging infrastructure.• Surge in precision medicine and companion diagnostics (CDx): The oncology landscape is rapidly shifting away from broad-spectrum chemotherapy toward targeted biologic and genomic therapies. This evolution relies heavily on companion diagnostics specialized assays designed to identify specific genetic mutations, biomarker expressions (e.g., EGFR, HER2, PD-L1), or chromosomal rearrangements in individual patients. Pharmaceutical developers and diagnostic companies are increasingly co-developing companion diagnostic kits alongside targeted drugs to ensure therapeutic efficacy, generating recurring revenue streams for molecular diagnostic assay platforms.
Market Challenges
• High capital costs and complex reimbursement hurdles: Deploying cutting-edge diagnostic equipment such as Next-Generation Sequencing (NGS) platforms, high-field MRI scanners, and PET-CT instruments requires substantial upfront capital expenditure alongside ongoing maintenance and skilled labor costs. Furthermore, navigating regional reimbursement frameworks presents a major bottleneck. Diagnostic providers frequently encounter delayed, inconsistent, or insufficient insurance coverage for novel multi-gene panels and liquid biopsy tests, creating financial risk for labs and limiting widespread adoption in cost-sensitive healthcare environments.• Shortage of specialized pathology and genomic talent: The growing reliance on complex molecular diagnostic outputs has highlighted a global deficit in qualified workforce personnel. Molecular biologists, bioinformaticians, and specialized surgical pathologists trained to interpret multi-omic sequencing data and intricate digital pathology slides are in short supply worldwide. This workforce bottleneck delays turnaround times for critical patient diagnostics and creates operational constraints, particularly for secondary hospitals and clinical diagnostic facilities attempting to expand their advanced diagnostic offerings.
Market Trends
• Expansion of liquid biopsies and minimal residual disease (MRD) testing: Liquid biopsy technologies which analyze circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and circulating tumor cells (CTCs) from standard blood samples are transforming clinical oncology workflows. Rather than replacing invasive tissue biopsies entirely, liquid biopsies are increasingly adopted for non-invasive early detection, real-time therapy selection, and monitoring post-treatment Minimal Residual Disease (MRD) to detect early cancer recurrence months before visible tumors appear on standard radiological scans.• Integration of artificial intelligence (AI) in digital pathology and imaging: Artificial intelligence and deep learning algorithms are becoming deeply embedded across diagnostic workflows to enhance accuracy and speed. In digital pathology, AI tools assist pathologists by automating cell counting, identifying micro-metastases, and analyzing histopathology slides with greater precision. Simultaneously, AI-enhanced diagnostic imaging software reduces scan acquisition times, improves image resolution, and aids radiologists in distinguishing malignant nodules from benign lesions on CT, MRI, and mammography scans.
Cancer Diagnostics Segmentation
| By Product Type | Consumables and reagents | |
| Instruments | ||
| By Technology | IVD testing | |
| Anatomic pathology | ||
| Diagnostic imaging | ||
| Biopsy | ||
| By Application | Breast Cancer | |
| Colorectal Cancer | ||
| Lung Cancer | ||
| Prostate Cancer | ||
| Others | ||
| By End User | Hospitals | |
| Diagnostic Centres | ||
| Research Institutes | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Russia | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| South America | Brazil | |
| Argentina | ||
| Colombia | ||
| MEA | United Arab Emirates | |
| Saudi Arabia | ||
| South Africa | ||
Reagents and consumables dominate the cancer diagnostics market because they are indispensable, repeatedly used materials required for routine cancer detection, tissue analysis, molecular testing, and biomarker identification, creating continuous demand across diagnostic laboratories and healthcare facilities. Reagents and consumables occupy a leading position in cancer diagnostics because virtually every laboratory testing workflow depends on materials that are consumed during sample preparation, chemical reactions, staining, detection, and result validation. Unlike diagnostic instruments, which can remain operational for several years, these materials must be replenished whenever additional tests are performed. Common examples include antibodies, assay kits, molecular probes, enzymes, buffers, staining solutions, extraction reagents, slides, specimen containers, and quality-control materials. In conventional histopathology, tissue specimens obtained through biopsies or surgery are preserved, processed, sectioned, stained, and examined under a microscope, with reagents supporting several stages of this process. Immunohistochemistry requires specific antibodies and detection chemicals to identify proteins within tumor tissue, helping pathologists classify cancers and assess biomarkers relevant to treatment decisions. Molecular diagnostic procedures, including polymerase chain reaction and next-generation sequencing, similarly require extraction chemicals, primers, probes, enzymes, and other assay-specific components to detect genetic alterations. These requirements extend beyond the initial diagnosis because patients may undergo additional testing when the disease progresses, returns after treatment, or develops characteristics that influence subsequent therapeutic choices. Laboratories must also use appropriate controls and validated materials to check analytical performance and maintain reliable results. The expansion of precision oncology has further increased the importance of specialised reagents designed to identify particular mutations, protein expressions, and other clinically meaningful tumor characteristics. Diagnostic platforms also frequently require compatible consumables, making reliable product supply essential for uninterrupted laboratory operations. As testing methods become more specialised, laboratories need a broader selection of reagents suited to different specimen types, analytical techniques, and cancer biomarkers. In vitro diagnostics (IVD) testing leads the cancer diagnostics technology segment and can be identified as its fastest-growing segment because laboratory-based analysis of blood, tissue, and other biological specimens supports cancer detection, tumor classification, biomarker assessment, and increasingly personalised treatment decisions. In vitro diagnostics plays a central role in cancer care because it enables laboratory professionals to investigate biological characteristics that cannot be reliably established through symptoms or physical examination alone. Depending on the suspected cancer and the clinical question, testing may involve tumor tissue, blood, bone marrow, or other biological specimens, with the selected method determined by the disease and the information required. Histopathological examination remains essential for many cancer diagnoses, while laboratory-based immunoassays, molecular techniques, cytogenetic methods, and other analytical procedures provide additional information about tumor biology. For example, polymerase chain reaction can identify selected genetic alterations, while next-generation sequencing can examine multiple genes to detect changes that may influence treatment selection. Immunohistochemistry can establish whether tumor cells express specific proteins, as demonstrated by HER2 testing in breast cancer, which helps clinicians determine whether HER2-directed treatment may be appropriate. Molecular testing can also identify certain alterations relevant to targeted therapies and support the selection of treatments for particular lung cancers and other malignancies. These applications make IVD useful not only at the point of initial diagnosis but also when clinicians need to refine a tumor classification or investigate biomarkers before choosing a treatment. The technology's importance is reinforced by the need for standardized laboratory procedures, validated assays, appropriate quality controls, and clinically interpretable results. Its potential for faster growth is associated with the expansion of precision oncology, wider availability of molecular testing, increasing use of multigene panels, and the development of assays that can detect clinically relevant changes in small or complex specimens. Some blood-based approaches, including circulating tumor DNA analysis, are also being investigated and adopted for selected clinical applications, although their suitability varies by cancer type and intended use. Breast cancer represents the largest application segment in cancer diagnostics because it is one of the most frequently diagnosed cancers among women worldwide and requires extensive screening, confirmatory testing, tumor characterization, and biomarker assessment throughout the care pathway. Breast cancer occupies a prominent position in cancer diagnostics because its substantial clinical burden has encouraged the development of established screening programmes, specialised imaging services, pathology workflows, and treatment-linked laboratory testing. According to the International Agency for Research on Cancer, breast cancer was the most commonly diagnosed cancer worldwide in 2020 and remained the most frequently diagnosed cancer among women in 2024, although lung cancer ranked first when both sexes were considered together. This distinction helps explain why breast cancer is particularly important when diagnostic applications are examined by individual disease category. Mammography is a central screening method because it can reveal suspicious changes before a lump becomes noticeable, allowing patients to undergo further assessment when indicated. An abnormal screening result does not automatically establish malignancy; diagnostic mammography, ultrasound, and sometimes magnetic resonance imaging may be used to investigate the finding. When necessary, a breast biopsy provides tissue for microscopic examination and confirmation of the diagnosis. Pathologists then determine the tumor’s characteristics, including its histological type, grade, and relevant biomarker profile. Tests for estrogen receptors, progesterone receptors, and HER2 are particularly important because their results can influence the selection of endocrine therapy or HER2-targeted treatment. Additional molecular investigations may be appropriate for particular patients and clinical circumstances. Diagnostic demand therefore extends beyond detecting a suspected tumor to establishing its biological behavior, evaluating lymph-node involvement where relevant, and providing information needed for treatment planning. Testing can also recur when a patient develops a new suspicious lesion, experiences a possible recurrence, or requires reassessment of tumor characteristics. Breast cancer care involves several coordinated specialties, including radiology, pathology, surgery, and oncology, which creates multiple diagnostic touchpoints within the same patient journey. Hospitals constitute the largest end-user segment in cancer diagnostics because they bring together diagnostic laboratories, imaging departments, biopsy services, specialist clinicians, and treatment facilities, enabling patients to receive coordinated cancer evaluation within a single healthcare institution. Hospitals hold an important position in cancer diagnostics because investigating a suspected malignancy frequently involves several clinical departments rather than one isolated laboratory test. A patient may initially present with symptoms, an abnormal screening result, or an incidental finding during an examination for another condition. Hospital teams can coordinate the subsequent assessment through radiology, laboratory medicine, pathology, surgery, and oncology, depending on the suspected tumor and the patient's clinical needs. Imaging examinations help locate suspicious lesions and assess their extent, while biopsy procedures provide tissue or cellular material for pathological confirmation when indicated. Hospital pathology laboratories process specimens, examine tissue morphology, and conduct additional investigations such as immunohistochemistry or molecular testing to establish tumor characteristics. These findings help clinicians distinguish between different cancer types and determine whether further testing is needed before treatment begins. Hospitals also manage complex cases requiring multidisciplinary review, particularly when diagnosis depends on combining imaging observations, histological findings, laboratory results, and information about the patient's medical history. Their diagnostic responsibilities continue after initial confirmation because some patients require reassessment during treatment, investigation of suspected recurrence, or evaluation of new symptoms. Cancer surgery generates additional tissue specimens for examination, and advanced treatment programmes may require specialised biomarker tests to determine eligibility for particular therapies. Large hospitals and specialised cancer centres may maintain their own laboratories and sophisticated diagnostic equipment, whereas other hospitals send selected specimens to external reference laboratories when particular expertise or technology is unavailable locally. Both arrangements reinforce hospitals' role as major users and purchasers of cancer diagnostic services, even when not every test is performed on their premises. Hospital laboratories also require trained pathologists, laboratory scientists, quality-management systems, specimen-tracking procedures, and reliable supplies of reagents and consumables. Their ability to integrate diagnostic findings with treatment planning makes them important settings for comprehensive cancer care. Although independent diagnostic laboratories and specialist outpatient centres also perform substantial testing, hospitals frequently handle patients with complicated conditions, invasive diagnostic procedures, multiple comorbidities, and immediate treatment needs.
to Download this information in a PDF
Cancer Diagnostics Market Regional Insights
North America leads the global cancer diagnostics market because its established healthcare infrastructure, extensive laboratory capabilities, strong adoption of advanced diagnostic technologies, and well-developed cancer screening and treatment systems support widespread use of diagnostic testing. North America's position in cancer diagnostics is supported by the combination of advanced medical infrastructure, established pathology services, access to specialised oncology care, and the integration of laboratory findings into clinical decision-making. The United States is a particularly important contributor because its healthcare system includes academic medical centres, comprehensive cancer centres, hospital laboratories, independent diagnostic providers, and specialised molecular testing facilities. The National Cancer Institute supports cancer research through programmes that strengthen diagnostic science, clinical investigation, and the translation of research findings into medical practice. In addition, the National Cancer Institute's Surveillance, Epidemiology, and End Results programme collects and publishes cancer incidence, survival, and mortality information, supporting population-level understanding of the disease and informing research and public health planning. Cancer screening and early-detection services also contribute to diagnostic activity, with established approaches for breast, cervical, colorectal, and other cancers used according to clinical guidelines and individual risk factors. • USA: The United States occupies a leading position in North American cancer diagnostics because its healthcare infrastructure supports a wide range of diagnostic activities, from routine screening and conventional pathology to specialized molecular investigations. The country also has established screening recommendations for several cancers, including breast and colorectal cancer, while cervical cancer screening uses established methods such as human papillomavirus testing and Pap testing.
to Download this information in a PDF
Key Development
- August 2026Precipio is strengthening its cancer diagnostics business through expanding commercialization of its proprietary diagnostic products and a growing customer pipeline. Its pathology infrastructure gives Precipio direct access to patient specimens and clinical workflows, supporting faster development and validation of new diagnostic solutions.
- August 2026Abbott is applying user-experience design to cancer diagnostic sample-collection packaging to make testing simpler and reduce friction for healthcare professionals and patients. Its cancer diagnostic sample-collection kits, including Cologuard, are being designed around the distinct needs of phlebotomists, pathologists, and at-home screening users.
- August 2026New Mexico Cancer Center became the first facility in New Mexico to offer Cerianna (FES) PET imaging for eligible patients with recurrent or metastatic ER-positive breast cancer. The imaging uses an estrogen-receptor-targeting radiotracer to identify ER-positive disease throughout the body.
- July 2026Ibex Medical Analytics received CE-IVDR certification for Ibex Breast ER, PR and Ki67, completing regulatory certification across its breast cancer diagnostic portfolio. The AI-powered solution automates biomarker quantification, improving scoring consistency while reducing manual pathology workload.
- June 2026Veracyte launched its Prosigna Breast Risk of Recurrence test to help identify early-stage breast cancer patients who could safely avoid chemotherapy. The genomic test analyzed the activity of 50 genes to assess recurrence risk and guide personalized treatment decisions.
- May 2026Roche Diagnostics Asia Pacific collaborated with AstraZeneca to accelerate a sustainable ecosystem for advanced pathology in breast and lung cancer. This partnership aims to enhance diagnostic capabilities and support better patient outcomes in breast and lung cancer treatment through advanced pathology solutions.
- May 2026The FDA approved Myriad Genetics' companion diagnostic for ovarian cancer, advancing precision medicine in cancer treatment. This approval enables clinicians to identify patients who may benefit from specific ovarian cancer therapies through genetic testing. The companion diagnostic supports targeted treatment decisions for ovarian cancer patients.
- March 2026Rhythm Biosciences highlighted the strategic importance of NATA accreditation for commercializing ColoSTAT, its blood-based colorectal cancer diagnostic test. The accreditation confirms compliance with ISO 15189:2022 requirements for clinical testing and supports delivery of the test through accredited laboratory services.
- October 2025DermaSensor secured $16 million to scale AI-powered skin cancer detection in primary care settings. The funding supports the deployment of the company's AI-driven diagnostic technology that enables primary care providers to detect skin cancer earlier and more accurately. This advancement brings sophisticated skin cancer detection capabilities to routine clinical practice.
- September 2025F. Hoffmann-La Roche’s VENTANA HER2 (4B5) test received CE-IVDR approval to support the assessment of HER2-ultralow status, enabling identification of metastatic breast cancer patients eligible for treatment with ENHERTU.
- July 2025Bern-based medtech company Compremium launched a human clinical study for its non-invasive thyroid cancer diagnostic device that measures tissue compressibility to better distinguish between benign and malignant nodules. The 18-month trial at Bern University Hospital targets patients with Bethesda IV nodules to help reduce unnecessary thyroid surgeries.
- July 2025Fred Hutch Cancer Center launched the Vanguard Study, the first trial under the Cancer Screening Research Network (CSRN), to assess the effectiveness of multi-cancer detection (MCD) blood tests in adults aged 45-75.
Companies Mentioned
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers
- Agilent Technologies, Inc.
- Thermo Fisher Scientific Inc
- Exact Sciences Corp
- Myriad Genetics, Inc
- QIAGEN N.V.
- Illumina, Inc
- Hologic, Inc.
- Becton, Dickinson and Company
- Roche Holding AG
- Sysmex Corporation
- Guardant Health, Inc.
- Natera, Inc.
- NeoGenomics Laboratories, Inc.
- bioMérieux SA
- Foundation Medicine, Inc.
- GRAIL, Inc.
- Tempus AI, Inc.
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. Global Cancer Diagnostics Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Region
- 6.3. Market Size and Forecast, By Geography
- 6.4. Market Size and Forecast, By Product Type
- 6.4.1. Market Size and Forecast, By Consumables and reagents
- 6.4.2. Market Size and Forecast, By Instruments
- 6.5. Market Size and Forecast, By Technology
- 6.6. Market Size and Forecast, By Application
- 6.7. Market Size and Forecast, By End User
- 7. North America Cancer Diagnostics Market Outlook
- 7.1. Market Size By Value
- 7.2. Market Share By Country
- 7.3. Market Size and Forecast, By Product Type
- 7.4. Market Size and Forecast, By Technology
- 7.5. Market Size and Forecast, By Application
- 7.6. Market Size and Forecast, By End User
- 7.7. United States Cancer Diagnostics Market Outlook
- 7.7.1. Market Size by Value
- 7.7.2. Market Size and Forecast By Product Type
- 7.7.3. Market Size and Forecast By Technology
- 7.7.4. Market Size and Forecast By Application
- 7.8. Canada Cancer Diagnostics Market Outlook
- 7.8.1. Market Size by Value
- 7.8.2. Market Size and Forecast By Product Type
- 7.8.3. Market Size and Forecast By Technology
- 7.8.4. Market Size and Forecast By Application
- 7.9. Mexico Cancer Diagnostics Market Outlook
- 7.9.1. Market Size by Value
- 7.9.2. Market Size and Forecast By Product Type
- 7.9.3. Market Size and Forecast By Technology
- 7.9.4. Market Size and Forecast By Application
- 8. Europe Cancer Diagnostics Market Outlook
- 8.1. Market Size By Value
- 8.2. Market Share By Country
- 8.3. Market Size and Forecast, By Product Type
- 8.4. Market Size and Forecast, By Technology
- 8.5. Market Size and Forecast, By Application
- 8.6. Market Size and Forecast, By End User
- 8.7. Germany Cancer Diagnostics Market Outlook
- 8.7.1. Market Size by Value
- 8.7.2. Market Size and Forecast By Product Type
- 8.7.3. Market Size and Forecast By Technology
- 8.7.4. Market Size and Forecast By Application
- 8.8. United Kingdom (UK) Cancer Diagnostics Market Outlook
- 8.8.1. Market Size by Value
- 8.8.2. Market Size and Forecast By Product Type
- 8.8.3. Market Size and Forecast By Technology
- 8.8.4. Market Size and Forecast By Application
- 8.9. France Cancer Diagnostics Market Outlook
- 8.9.1. Market Size by Value
- 8.9.2. Market Size and Forecast By Product Type
- 8.9.3. Market Size and Forecast By Technology
- 8.9.4. Market Size and Forecast By Application
- 8.10. Italy Cancer Diagnostics Market Outlook
- 8.10.1. Market Size by Value
- 8.10.2. Market Size and Forecast By Product Type
- 8.10.3. Market Size and Forecast By Technology
- 8.10.4. Market Size and Forecast By Application
- 8.11. Spain Cancer Diagnostics Market Outlook
- 8.11.1. Market Size by Value
- 8.11.2. Market Size and Forecast By Product Type
- 8.11.3. Market Size and Forecast By Technology
- 8.11.4. Market Size and Forecast By Application
- 8.12. Russia Cancer Diagnostics Market Outlook
- 8.12.1. Market Size by Value
- 8.12.2. Market Size and Forecast By Product Type
- 8.12.3. Market Size and Forecast By Technology
- 8.12.4. Market Size and Forecast By Application
- 9. Asia-Pacific Cancer Diagnostics Market Outlook
- 9.1. Market Size By Value
- 9.2. Market Share By Country
- 9.3. Market Size and Forecast, By Product Type
- 9.4. Market Size and Forecast, By Technology
- 9.5. Market Size and Forecast, By Application
- 9.6. Market Size and Forecast, By End User
- 9.7. China Cancer Diagnostics Market Outlook
- 9.7.1. Market Size by Value
- 9.7.2. Market Size and Forecast By Product Type
- 9.7.3. Market Size and Forecast By Technology
- 9.7.4. Market Size and Forecast By Application
- 9.8. Japan Cancer Diagnostics Market Outlook
- 9.8.1. Market Size by Value
- 9.8.2. Market Size and Forecast By Product Type
- 9.8.3. Market Size and Forecast By Technology
- 9.8.4. Market Size and Forecast By Application
- 9.9. India Cancer Diagnostics Market Outlook
- 9.9.1. Market Size by Value
- 9.9.2. Market Size and Forecast By Product Type
- 9.9.3. Market Size and Forecast By Technology
- 9.9.4. Market Size and Forecast By Application
- 9.10. Australia Cancer Diagnostics Market Outlook
- 9.10.1. Market Size by Value
- 9.10.2. Market Size and Forecast By Product Type
- 9.10.3. Market Size and Forecast By Technology
- 9.10.4. Market Size and Forecast By Application
- 9.11. South Korea Cancer Diagnostics Market Outlook
- 9.11.1. Market Size by Value
- 9.11.2. Market Size and Forecast By Product Type
- 9.11.3. Market Size and Forecast By Technology
- 9.11.4. Market Size and Forecast By Application
- 10. South America Cancer Diagnostics Market Outlook
- 10.1. Market Size By Value
- 10.2. Market Share By Country
- 10.3. Market Size and Forecast, By Product Type
- 10.4. Market Size and Forecast, By Technology
- 10.5. Market Size and Forecast, By Application
- 10.6. Market Size and Forecast, By End User
- 10.7. Brazil Cancer Diagnostics Market Outlook
- 10.7.1. Market Size by Value
- 10.7.2. Market Size and Forecast By Product Type
- 10.7.3. Market Size and Forecast By Technology
- 10.7.4. Market Size and Forecast By Application
- 10.8. Argentina Cancer Diagnostics Market Outlook
- 10.8.1. Market Size by Value
- 10.8.2. Market Size and Forecast By Product Type
- 10.8.3. Market Size and Forecast By Technology
- 10.8.4. Market Size and Forecast By Application
- 10.9. Colombia Cancer Diagnostics Market Outlook
- 10.9.1. Market Size by Value
- 10.9.2. Market Size and Forecast By Product Type
- 10.9.3. Market Size and Forecast By Technology
- 10.9.4. Market Size and Forecast By Application
- 11. Middle East & Africa Cancer Diagnostics Market Outlook
- 11.1. Market Size By Value
- 11.2. Market Share By Country
- 11.3. Market Size and Forecast, By Product Type
- 11.4. Market Size and Forecast, By Technology
- 11.5. Market Size and Forecast, By Application
- 11.6. Market Size and Forecast, By End User
- 11.7. United Arab Emirates (UAE) Cancer Diagnostics Market Outlook
- 11.7.1. Market Size by Value
- 11.7.2. Market Size and Forecast By Product Type
- 11.7.3. Market Size and Forecast By Technology
- 11.7.4. Market Size and Forecast By Application
- 11.8. Saudi Arabia Cancer Diagnostics Market Outlook
- 11.8.1. Market Size by Value
- 11.8.2. Market Size and Forecast By Product Type
- 11.8.3. Market Size and Forecast By Technology
- 11.8.4. Market Size and Forecast By Application
- 11.9. South Africa Cancer Diagnostics Market Outlook
- 11.9.1. Market Size by Value
- 11.9.2. Market Size and Forecast By Product Type
- 11.9.3. Market Size and Forecast By Technology
- 11.9.4. Market Size and Forecast By Application
- 12. Competitive Landscape
- 12.1. Competitive Dashboard
- 12.2. Business Strategies Adopted by Key Players
- 12.3. Key Players Market Share Insights and Analysis, 2025
- 12.4. Key Players Market Positioning Matrix
- 12.5. Porter's Five Forces
- 12.6. Company Profile
- 12.6.1. Thermo Fisher Scientific Inc.
- 12.6.1.1. Company Snapshot
- 12.6.1.2. Company Overview
- 12.6.1.3. Financial Highlights
- 12.6.1.4. Geographic Insights
- 12.6.1.5. Business Segment & Performance
- 12.6.1.6. Product Portfolio
- 12.6.1.7. Key Executives
- 12.6.1.8. Strategic Moves & Developments
- 12.6.2. Abbott Laboratories
- 12.6.3. Agilent Technologies, Inc.
- 12.6.4. Roche Diagnostics
- 12.6.5. Danaher Corporation
- 12.6.6. Siemens Healthineers AG
- 12.6.7. QIAGEN N.V.
- 12.6.8. Becton, Dickinson and Company (BD)
- 12.6.9. Illumina, Inc.
- 12.6.10. Hologic, Inc.
- 12.6.11. bioMérieux SA
- 12.6.12. Foundation Medicine, Inc.
- 12.6.13. Sysmex Corporation
- 12.6.14. NeoGenomics Laboratories, Inc.
- 12.6.15. Myriad Genetics, Inc.
- 12.6.16. Exact Sciences Corporation
- 12.6.17. Guardant Health, Inc.
- 12.6.18. GRAIL, Inc.
- 12.6.19. Natera, Inc.
- 12.6.20. Tempus AI, Inc.
- 13. Strategic Recommendations
- 14. Annexure
- 14.1. FAQ`s
- 14.2. Notes
- 15. Disclaimer
Table 2: Influencing Factors for Cancer Diagnostics Market, 2025
Table 3: Top 10 Counties Economic Snapshot 2024
Table 4: Economic Snapshot of Other Prominent Countries 2022
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Cancer Diagnostics Market Size and Forecast, By Geography (2020 to 2031F) (In USD Billion)
Table 7: Global Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 8: Global Cancer Diagnostics Market Size and Forecast, By Consumables and reagents (2020 to 2031F) (In USD Billion)
Table 9: Global Cancer Diagnostics Market Size and Forecast, By Instruments (2020 to 2031F) (In USD Billion)
Table 10: Global Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 11: Global Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 12: Global Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 13: North America Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 14: North America Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 15: North America Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 16: North America Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 17: United States Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 18: United States Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 19: United States Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 20: Canada Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 21: Canada Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 22: Canada Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 23: Mexico Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 24: Mexico Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 25: Mexico Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 26: Europe Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 27: Europe Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 28: Europe Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 29: Europe Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 30: Germany Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 31: Germany Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 32: Germany Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 33: United Kingdom (UK) Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 34: United Kingdom (UK) Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 35: United Kingdom (UK) Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 36: France Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 37: France Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 38: France Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 39: Italy Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 40: Italy Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 41: Italy Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 42: Spain Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 43: Spain Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 44: Spain Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 45: Russia Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 46: Russia Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 47: Russia Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 48: Asia-Pacific Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 49: Asia-Pacific Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 50: Asia-Pacific Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 51: Asia-Pacific Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 52: China Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 53: China Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 54: China Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 55: Japan Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 56: Japan Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 57: Japan Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 58: India Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 59: India Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 60: India Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 61: Australia Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 62: Australia Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 63: Australia Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 64: South Korea Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 65: South Korea Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 66: South Korea Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 67: South America Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 68: South America Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 69: South America Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 70: South America Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 71: Brazil Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 72: Brazil Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 73: Brazil Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 74: Argentina Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 75: Argentina Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 76: Argentina Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 77: Colombia Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 78: Colombia Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 79: Colombia Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 80: Middle East & Africa Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 81: Middle East & Africa Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 82: Middle East & Africa Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 83: Middle East & Africa Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 84: United Arab Emirates (UAE) Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 85: United Arab Emirates (UAE) Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 86: United Arab Emirates (UAE) Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 87: Saudi Arabia Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 88: Saudi Arabia Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 89: Saudi Arabia Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 90: South Africa Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 91: South Africa Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 92: South Africa Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 93: Competitive Dashboard of top 5 players, 2025
Table 94: Key Players Market Share Insights and Analysis for Cancer Diagnostics Market 2025
Figure 2: Market attractiveness Index, By Region 2031F
Figure 3: Market attractiveness Index, By Segment 2031F
Figure 4: Global Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Global Cancer Diagnostics Market Share By Region (2025)
Figure 6: North America Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: North America Cancer Diagnostics Market Share By Country (2025)
Figure 8: US Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Canada Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 10: Mexico Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 11: Europe Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 12: Europe Cancer Diagnostics Market Share By Country (2025)
Figure 13: Germany Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 14: United Kingdom (UK) Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 15: France Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 16: Italy Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 17: Spain Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 18: Russia Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 19: Asia-Pacific Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 20: Asia-Pacific Cancer Diagnostics Market Share By Country (2025)
Figure 21: China Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 22: Japan Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 23: India Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 24: Australia Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 25: South Korea Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 26: South America Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 27: South America Cancer Diagnostics Market Share By Country (2025)
Figure 28: Brazil Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 29: Argentina Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 30: Colombia Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 31: Middle East & Africa Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 32: Middle East & Africa Cancer Diagnostics Market Share By Country (2025)
Figure 33: United Arab Emirates (UAE) Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 34: Saudi Arabia Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 35: South Africa Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 36: Porter's Five Forces of Global Cancer Diagnostics Market
Cancer Diagnostics Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Our Clients
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (27 October, 2026)
- Notify To Team (27 October, 2026)
- Report updation (28 October, 2026)
- Report Quality Check (28 October, 2026)
- Report Dispatch (29 October, 2026)
- Hard Copy
Recently Viewed Products
Global Cancer Diagnostics Market Outlook, 2031
We are friendly and approachable, give us a call.